Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-048/00
C07H-021/04
C07H-021/02
C12N-015/63
C12N-015/85
출원번호
US-0437899
(2009-05-08)
등록번호
US-8258111
(2012-09-04)
발명자
/ 주소
Shen, Jikui
Kelnar, Kevin
Shelton, Jeffrey
Brown, David
Campochiaro, Peter
출원인 / 주소
The Johns Hopkins University
대리인 / 주소
Fulbright & Jaworski L.L.P.
인용정보
피인용 횟수 :
11인용 특허 :
124
초록▼
The present invention concerns methods and compositions for diagnosing and/or treating vascular diseases including cancer, cardiac diseases, vascular diseases of the eye, and inflammatory diseases. The methods involve measuring the levels of one or multiple miRNAs in patient samples and using the te
The present invention concerns methods and compositions for diagnosing and/or treating vascular diseases including cancer, cardiac diseases, vascular diseases of the eye, and inflammatory diseases. The methods involve measuring the levels of one or multiple miRNAs in patient samples and using the test results to diagnose and/or predict an optimal treatment regimen for the patient. Compositions described in the invention include nucleic acids that function as miRNAs or miRNA inhibitors that can be introduced to a patient to reduce or increase vascularization as needed.
대표청구항▼
1. A method for reducing vascularization in a subject or tissue comprising administering to the subject or tissue in need of such a reduction, in an amount sufficient to reduce vascularization, one or more nucleic acid molecules comprising a nucleic acid sequence 17 to 110 nucleotides in length that
1. A method for reducing vascularization in a subject or tissue comprising administering to the subject or tissue in need of such a reduction, in an amount sufficient to reduce vascularization, one or more nucleic acid molecules comprising a nucleic acid sequence 17 to 110 nucleotides in length that is at least 80% identical to miR-31. 2. The method of claim 1, wherein the nucleic acid is administered topically, enterally, parenterally or intravitreally. 3. The method of claim 1, wherein the nucleic acid molecule is an RNA. 4. The method of claim 3, wherein the RNA comprises a complementary RNA region that has noncomplementarity with the miRNA in the last 1, 2, 3, 4, and/or 5 nucleotides of the complementary region. 5. The method of claim 4, wherein the RNA comprises a hairpin structure. 6. The method of claim 1, wherein the RNA is 17 to 35 nucleotides in length and comprises two RNA strands, wherein the complementary strand is 1) between 60 and 90% complementary to the miRNA sequence or 2) has a nucleotide analog or modified nucleotide. 7. The method of claim 6, wherein the RNA molecule includes a nucleotide analog or a modified nucleotide in the complementary strand. 8. The method of claim 1, wherein the nucleic acid molecule is a DNA molecule or is produced from a DNA molecule. 9. A method for reducing vascularization in a subject or tissue comprising administering to the subject or tissue in need of such a reduction, in an amount sufficient to reduce vascularization, a vector comprising a nucleic acid molecule encoding a nucleic acid sequence that comprises a sequence that is at least 80% identical to miR-31. 10. The method of claim 1, wherein the subject has, is at risk of developing, or is suspected of having ocular or retinal/choroidal neovascular diseases, cancer, diabetic nephropathy, rheumatoid arthritis, atherosclerotic plaques, endometriosis, Crohn's disease, uterine fibroids, benign prostatic hyperplasia, or psoriasis. 11. The method of claim 6, wherein the modified nucleotide is a sugar modification. 12. The method of claim 6, wherein the complementary strand comprises a replacement group for the phosphate or hydroxyl group. 13. The method of claim 9, wherein the vector is comprised in a lipid or viral delivery vehicle. 14. The method of claim 9, wherein the vector is a viral vector. 15. The method of claim 9, wherein the vector is administered topically, enterally, parenterally or intravitreally. 16. The method of claim 9, wherein the subject has, is at risk of developing, or is suspected of having ocular or retinal/choroidal neovascular diseases, cancer, diabetic nephropathy, rheumatoid arthritis, atherosclerotic plaques, endometriosis, Crohn's disease, uterine fibroids, benign prostatic hyperplasia, or psoriasis.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (124)
Chris A. Buhr ; Mark Matteucci, 2' Modified oligonucleotides.
Menchen Steven M. (Fremont CA) Lee Linda G. (Palo Alto CA) Connell Charles R. (Redwood City CA) Hershey N. Davis (San Carlos CA) Chakerian Vergine (San Mateo CA) Woo Sam (Redwood City CA) Fung Steven, 4,7-dichlorofluorescein dyes as molecular probes.
Milburn Susan C. (Austin TX) Goldrick Marianna (Pflugerville TX) Winkler Matthew (Austin TX), Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reac.
Milburn, Susan C.; Goldrick, Marianna; Winkler, Matthew, Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions.
Milburn, Susan; Goldrick, Marianna; Winkler, Matthew, Compositions and methods for increasing the yields of the in vitro RNA transcription and other polynucleotide synthetic reactions.
Von Wronski,Mathew A.; Marinelli,Edmund R.; Nunn,Adrian D.; Pillai,Radhakrishna; Ramalingam,Kondareddiar; Tweedle,Michael F.; Linder,Karen; Nanjappan,Palaniappa; Raju,Natarajan, Compounds for targeting endothelial cells, compositions containing the same and methods for their use.
Sobol Robert E. (LaJolla CA) Green Mark R. (San Diego CA) Kawasaki Ernest S. (Richmond CA), Detection of carcinoma metastases by nucleic acid amplification.
Pardridge William M. ; Boado Ruben J., Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology.
Maruyama,Toshiaki; Frederickson,Shana; Bowdish,Katherine S.; Renshaw,Mark; Lin,Ying Chi, Engineered templates and their use in single primer amplification.
Lockhart David J. ; Brown Eugene L. ; Wong Gordon G. ; Chee Mark S. ; Gingeras Thomas R., Expression monitoring by hybridization to high density oligonucleotide arrays.
Sedlacek Hans-Harald,DEX ; Bosslet Klaus,DEX ; Muller Rolf,DEX, Gene therapy of tumors with an endothelial cell-specific, cell cycle-dependent active compound.
Semple, Sean C.; Klimuk, Sandra K.; Harasym, Troy; Hope, Michael J.; Ansell, Steven M.; Cullis, Pieter; Scherrer, Peter; Debeyer, Dan, Lipid-encapsulated polyanionic nucleic acid.
Jonathan Marc Rothberg ; Michael W. Deem ; John W. Simpson, Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing.
Rothberg Jonathan Marc ; Deem Michael W. ; Simpson John W., Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing.
Livak Kenneth J. (San Jose CA) Flood Susan J. A. (Fremont CA) Marmaro Jeffrey (Foster City CA), Method for detecting nucleic acid amplification using self-quenching fluorescence probe.
Lloyd,John Scott; Weston,Anthony; Cardy,Donald Leonard Nicholas, Method for detecting nucleic acid target sequences involving in vitro transcription from an RNA polymerase promoter.
Benner Steven A. (Hadlaubstrasse 151 CH-8006 Zurich CHX), Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases.
van Gemen, Bob; Timmermans, Eveline Catherina A. C.; de Ronde, Anthonij; Dobbelaer, Irene Johanna M., Method of determining therapeutic activity and/or possible side-effects of a medicament.
Dai,Hongyue; He,Yudong; Linsley,Peter S.; Mao,Mao; Roberts,Christopher J.; Van't Veer,Laura Johanna; Van de Vijver,Marc J.; Bernards,Rene; Hart,A. A. M., Methods of assigning treatment to breast cancer patients.
Huang,Mingxian; Wu,Lei; Wang,Xiaobo; Xu,Junquan; Tao,Guo Liang; Rothwarf,David M., Microdevices having a preferential axis of magnetization and uses thereof.
David J. Lockhart ; Mark Chee ; Kevin Gunderson ; Lai Chaoqiang ; Lisa Wodicka ; Maureen T. Cronin ; Danny Lee ; Huu M. Tran ; Hajime Matsuzaki, Nucleic acid analysis techniques.
Duck Peter (Ottawa CAX) Bender Robert (Ottawa CAX) Crosby William (Saskatoon CAX) Robertson John G. (L\Ange Gardien CAX), Nucleic acid compositions with scissile linkage useful for detecting nucleic acid sequences.
Esau, Christine; Lollo, Bridget; Bennett, C. Frank; Freier, Susan M.; Griffey, Richard H.; Baker, Brenda F.; Vickers, Timothy A.; Marcusson, Eric G.; Koller, Erich; Swayze, Eric E.; Jain, Ravi; Bhat, Balkrishen; Peralta, Eigen, Oligomeric compounds and compositions for use in modulation of small non-coding RNAs.
Keys, Daniel A.; Farooqui, Firdous; Reddy, M. Parameswara, Oligonucleotide probes for detecting nucleic acids through changes in flourescence resonance energy transfer.
Van Gelder Russell N. (2200 Divot Dr. Crystal Lake MD 63131) Von Zastrow Mark E. (11570 Buena Vista Dr. Los Altos CA 94022) Barchas Jack D. (1900 Rittenhouse Sq. #18A Philadelphia PA 19103) Eberwine , Process for amplifying a target polynucleotide sequence using a single primer-promoter complex.
Mullis Kary B. (Kensington CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or-cloning nucleic acid sequences.
Bergot B. John (Redwood City CA) Chakerian Vergine (San Mateo CA) Connell Charles R. (Redwood City CA) Eadie J. Scott (Indianapolis IN) Fung Steven (Palo Alto CA) Hershey N. Davis (San Carlos CA) Lee, Spectrally resolvable rhodamine dyes for nucleic acid sequence determination.
Kazlauskas, Andrius; Staniszewska, Magdalena; Romano, Carmelo; Landers, Robert; Bingaman, David P., Compositions and methods for treatment of angiogenesis-associated ocular disorders.
Shen, Jikui; Kelnar, Kevin; Shelton, Jeffrey; Brown, David; Campochiaro, Peter, Compositions and methods related to miRNA modulation of neovascularization or angiogenesis.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.